4月28日晚间,诺诚健华发布了2024年年报,高调宣布其核心产品BTK抑制剂奥布替尼收入首次超过10亿元,迎来重大里程碑。但比起2024年的收入,更让行业关注的,是近日奥布替尼获国家药监局批准,用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)患者,同时被《中国临床肿瘤学会(CSCO)淋巴瘤诊疗指南2025》列为CLL/SLL一线治疗的I级推荐方案。《CSCO淋巴瘤诊疗指南》、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.